| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5657511 | Clinical Gastroenterology and Hepatology | 2017 | 62 Pages |
Abstract
An indirect comparison of DAA-based treatments, using Bayesian network meta-analysis, found regimens containing sofosbuvir and velpatasvir to be the best option for patients with HCV genotype 3 infection. Our analyses indicated that ribavirin significantly increases SVR rates and should be considered if tolerated.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Floor A.C. Berden, Bryan R.R.Z. Aaldering, Hans Groenewoud, Joanna IntHout, Wietske Kievit, Joost P.H. Drenth,